Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice
Webinar Overview:
Discover how to access previously untapped sources of high-affinity antibodies. In this presentation, Dr. Joe de Rutte from Partillion Bioscience and Dr. Dilip Challa from Alloy Therapeutics discuss how breakthrough technology can help:
Access Plasma Cell Diversity: Discover how nanovial technology enables screening of plasma cells from ATX-GK transgenic mice harboring fully human antibody heavy and light chain repertoires, capturing high-affinity antibodies previously inaccessible due to a lack or surface Immunoglobutin expression
- Achieve Superior Binding Performance: Learn how this approach generated multiple picomolar binding clones with greater binding affinity than B-cell derived antibodies
- Streamline High-Throughput Screening: Explore how over a million single-cell compartments can be screened leveraging existing flow cytometry equipment
- Generate Developable Candidates: Gain insights into how this workflow delivers diverse clonotypes with strong developability profiles
The above is a free preview. If you’d like full to access the recording from our recent webinar-Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice—please submit your contact information. You will receive an email shortly with the recording link and a password.
About the Speakers:
Joe de Rutte, PhD
Co-Founder and CEO of Partillion Bioscience
Dr. Joe de Rutte is Co-Founder and CEO of Partillion Bioscience, a venture-backed startup commercializing the lab-on-a-particle technology he pioneered. While pursuing his PhD at UCLA, Dr. de Rutte developed a novel microparticle-based approach to form uniform sub-nanoliter compartments, enabling researchers to perform complex single-cell and molecular assays using common laboratory equipment. His breakthrough work in high-throughput sorting of single cells based on secreted products was recognized with the Top Innovation Award at SLAS 2020 and New Product Award in 2022. Dr. de Rutte received his PhD in Bioengineering from UCLA and his Master’s degree in Mechanical Engineering from UC Santa Barbara, where he specialized in microfluidics and flow cytometry.
Dilip Challa, PhD
Senior Scientist, Single-Cell Platforms Alloy Therapeutics
Dr. Dilip Challa is a Senior Scientist in the B Cell Group at Alloy Therapeutics, where he leads the discovery of antibodies using diverse single-cell platforms and Alloy’s humanized transgenic mice. He brings over 10 years of research experience in immunology, with expertise in T cell biology, antibody engineering, tumor immunology, and autoimmunity. Prior to joining Alloy, he served as a Research Scientist at the Broad Institute of MIT and Harvard focusing on immuno-oncology target validation and high-throughput assay development, as well as contributed to drug development at AVANTGEN.
Dr. Challa received his PhD in Immunology from UT Southwestern Medical Center, after which he conducted postdoctoral research at Texas A&M University.